Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital

Lugyanti Sukrisman Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, IndonesiaCorrespondence: Lugyanti Sukrisman, Division of Hematology and Medical Oncology, Department of Internal M...

Full description

Bibliographic Details
Main Author: Sukrisman L
Format: Article
Language:English
Published: Dove Medical Press 2022-09-01
Series:Journal of Blood Medicine
Subjects:
Online Access:https://www.dovepress.com/clinical-characteristics-and-prognostic-risks-of-philadelphia-negative-peer-reviewed-fulltext-article-JBM
_version_ 1798033297969774592
author Sukrisman L
author_facet Sukrisman L
author_sort Sukrisman L
collection DOAJ
description Lugyanti Sukrisman Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, IndonesiaCorrespondence: Lugyanti Sukrisman, Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Email lugyanti@gmail.comBackground: Philadelphia-negative myeloproliferative neoplasms (Ph-MPNs) are clonal hematopoietic cell malignancy that comprises polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). They prone to develop thrombosis, bleeding, fibrotic progression, and leukemic transformation. We aimed to study clinical characteristics, thrombosis complications, and prognostic risk in Indonesians with Ph-MPNs.Methods: This was a single-center retrospective cross-sectional study, including patients with Ph-MPNs who attended Hematology and Medical Oncology outpatient clinic at Cipto Mangunkusumo General Hospital, Jakarta, between 2016 and 2021. Demographic data, clinical characteristics, previous antiplatelet treatment, baseline laboratory data, JAK2V617F mutation, and treatment were reviewed for analysis. The prognostic risk model was assessed for PV (IPSS), ET (IPSET-thrombosis), and PMF (IPSS and DIPPS) patients.Results: One hundred forty-six patients were classified as PV (31.5%), ET (38.4%), and PMF (30.1%) with median ages of 54, 53.5, and 55 years, respectively. PMF presented with the most diverse clinical presentations. JAK2V617 mutations were detected in 82%, 42.5%, and 76.5% of PV, ET, and PMF patients. PV had the highest thrombosis event pre/at diagnosis (26.1%), with predominantly arterial thrombosis. Bleeding occurred more in PMF (20.5%). Phlebotomy and hydroxyurea are the only treatment available for Ph-MPNs in the government hospital in Indonesia. IPSS intermediate risk in PV (47.8%), IPSET-thrombosis low risk in ET (46.4%), and IPSS and DIPSS intermediate-2 in PMF (38.6% and 50% respectively) were the most common risk groups.Conclusion: Essential thrombocythemia was the most prevalent Ph-MPNs in Indonesia. Arterial thrombosis was the highest thrombosis event pre/at diagnosis in PV despite IPSET-thrombosis low risk being the most common risk group. In JAK2V617 mutation-positive MPN population, thrombosis event was also the highest in PV.Keywords: Ph-MPNs, clinical characteristics, thrombosis, prognosis
first_indexed 2024-04-11T20:28:03Z
format Article
id doaj.art-525f539900cd4c85b1d614835845b3b3
institution Directory Open Access Journal
issn 1179-2736
language English
last_indexed 2024-04-11T20:28:03Z
publishDate 2022-09-01
publisher Dove Medical Press
record_format Article
series Journal of Blood Medicine
spelling doaj.art-525f539900cd4c85b1d614835845b3b32022-12-22T04:04:36ZengDove Medical PressJournal of Blood Medicine1179-27362022-09-01Volume 1349550378172Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General HospitalSukrisman LLugyanti Sukrisman Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, IndonesiaCorrespondence: Lugyanti Sukrisman, Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Email lugyanti@gmail.comBackground: Philadelphia-negative myeloproliferative neoplasms (Ph-MPNs) are clonal hematopoietic cell malignancy that comprises polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). They prone to develop thrombosis, bleeding, fibrotic progression, and leukemic transformation. We aimed to study clinical characteristics, thrombosis complications, and prognostic risk in Indonesians with Ph-MPNs.Methods: This was a single-center retrospective cross-sectional study, including patients with Ph-MPNs who attended Hematology and Medical Oncology outpatient clinic at Cipto Mangunkusumo General Hospital, Jakarta, between 2016 and 2021. Demographic data, clinical characteristics, previous antiplatelet treatment, baseline laboratory data, JAK2V617F mutation, and treatment were reviewed for analysis. The prognostic risk model was assessed for PV (IPSS), ET (IPSET-thrombosis), and PMF (IPSS and DIPPS) patients.Results: One hundred forty-six patients were classified as PV (31.5%), ET (38.4%), and PMF (30.1%) with median ages of 54, 53.5, and 55 years, respectively. PMF presented with the most diverse clinical presentations. JAK2V617 mutations were detected in 82%, 42.5%, and 76.5% of PV, ET, and PMF patients. PV had the highest thrombosis event pre/at diagnosis (26.1%), with predominantly arterial thrombosis. Bleeding occurred more in PMF (20.5%). Phlebotomy and hydroxyurea are the only treatment available for Ph-MPNs in the government hospital in Indonesia. IPSS intermediate risk in PV (47.8%), IPSET-thrombosis low risk in ET (46.4%), and IPSS and DIPSS intermediate-2 in PMF (38.6% and 50% respectively) were the most common risk groups.Conclusion: Essential thrombocythemia was the most prevalent Ph-MPNs in Indonesia. Arterial thrombosis was the highest thrombosis event pre/at diagnosis in PV despite IPSET-thrombosis low risk being the most common risk group. In JAK2V617 mutation-positive MPN population, thrombosis event was also the highest in PV.Keywords: Ph-MPNs, clinical characteristics, thrombosis, prognosishttps://www.dovepress.com/clinical-characteristics-and-prognostic-risks-of-philadelphia-negative-peer-reviewed-fulltext-article-JBMph-mpnsclinical characteristicsthrombosisprognosis
spellingShingle Sukrisman L
Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital
Journal of Blood Medicine
ph-mpns
clinical characteristics
thrombosis
prognosis
title Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital
title_full Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital
title_fullStr Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital
title_full_unstemmed Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital
title_short Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital
title_sort clinical characteristics and prognostic risks of philadelphia negative myeloproliferative neoplasms at cipto mangunkusumo general hospital
topic ph-mpns
clinical characteristics
thrombosis
prognosis
url https://www.dovepress.com/clinical-characteristics-and-prognostic-risks-of-philadelphia-negative-peer-reviewed-fulltext-article-JBM
work_keys_str_mv AT sukrismanl clinicalcharacteristicsandprognosticrisksofphiladelphianegativemyeloproliferativeneoplasmsatciptomangunkusumogeneralhospital